Neonatal tetanus remains a major health problem in developing countries. )·3 In these environments with limited critical care facilities most patients with tetanus die from respiratory muscle spasm in the first week of the illness. 3 . 4 Severe tachycardia alone, in the absence of peripheral vasoconstriction, is the earliest manifestation of the sympathetic over-activity associated with tetanus. 5 • 6 Sinus tachycardia per se is usually a benign cardiac arrhythmia but if severe enough can cause cardiac decompensation and therefore requires treatment. 7 We describe a case of neonatal tetanus complicated by severe sinus tachycardia which was successfuly treated with esmolol.
CASE REPORT
An eight-day-old male infant presented to hospital with seizures and severe generalised spasms causing cyanosis. He had been born at home without any medical or nursing attendance and the umbilical cord had been cut with non-sterile scissors. He was intubated, sedated, and mechanically ventilated. Investigations excluded an intracranial infection or haemorrhage or a metabolic cause for these spasms, and a diagnosis of neonatal tetanus was made. He was given penicillin and 500 IU of anti-tetanus globulin and was transferred to Baragwanath Hospital Intensive Care Unit (lCU) for further management.
On admission to ICU his temperature was 37°C, heart rate 136 beats/min, blood pressure 50 mmHg systolic on palpation and perfusion was good. He weighed 2.4 kg. The rest of the physical examination was normal except for generalised tetanic spasms provoked by any stimulation. He was sedated with morphine and diazepam (0.5 mg/hour of each), paralysed with pancuronium 0.5 mg/hour and mechanically ventilated. The pulse rate and systolic blood pressure remained stable for 24 hours, with respective ranges of 125-150 beats/min and 50-70 mmHg during that time period. At this stage because spasms recurred, the doses of sedatives and pancuronium were doubled. On day 4 of admission he had two episodes of tachycardia with heart rate greater than 180 beats/min, each of these lasting about two hours. During these episodes the systolic blood pressure and oxygen saturation as measured with pulse oximetry (Sa02) remained unchanged. There was no concurrent pyrexia, hypoxia, evidence of sepsis or failure of sedation.
The following day the tachycardia became persistent with peaks in heart rate of 220 beats/min. During this time the systolic blood pressure ranged between 70 and 90 mmHg, but the patient's Sa02 fell to less than 90070 whenever his heart rate exceeded 200 beats/min. Daily blood cultures and blood counts showed no evidence of sepsis. The cause for the tachycardia was therefore presumed to be sympathetic overactivity. As episodes of severe tachycardia with decreases in Sa02 became frequent, we attempted to reduce the patient's heart rate. Esmolol, an ultra-short-acting f)-antagonist, was administered, initially as a bolus of 2.5 mg (1000 p,g/kg) over one minute followed by an infusion at 120 p,g/kg/min. The heart rate decreased during the bolus injection to 146 beats/min and remained between 130 and 160 beats/min with the continuous infusion. Systolic blood pressure changed from 100 to 80 mmHg with administration of esmolol. The patient then remained haemodynamically stable. After eight hours esmolol was gradually weaned and the heart rate and blood pressure remained within the normal range for age throughout the rest of the patient's ICU stay. The child recovered completely and was discharged to the general paediatric wards.
The routine monitoring practices of our ICU were used in this patient. These consist of continuous pulse rate display and non-invasive blood pressure measurements. In neonates and potential long-stay patients, it is our policy to use arterial lines for regular measurement of arterial blood gases when necessary, and not routinely for blood pressure monitoring.
DISCUSSION
In infants, sinus tachycardia is an appropriate response to various stimuli. It is usually benign and resolves either spontaneously or with removal of the cause. However, on occasion, the tachycardia impairs cardiac output and requires treatment. 7 Standard antiarrhythmic agents all have disadvantages. Digoxin is usually ineffective. Verapamil is not recommended for use in infants due to potentially cardio-depressive properties. ' Adenosine has become the recommended treatment for supra-ventricular tachycardias in children, but, as it has no f)-antagonist activity, it might not be appropriate in this clinical situation. 9 In the sympathetic overactivity of tetanus, increased catecholamine release results in both 0:-and f)-adrenergic effects. The o:-agonistic action is primarily arterial and venous vasoconstriction producing increased peripheral vascular resistance. i3-agonists act on the myocardium increasing cardiac output. These effects both produce hypertension and tachycardia and cannot be clinically separated. In addition, as the 0:and f)-agonistic effects do vary from patient to patient, either may dominate with a similar clinical picture. Therefore, blocking an individual pathway, as with the use of f)-antagonists, will be either helpful or detrimental to the patients depending on which pathway is predominant. In the cases reported where f)-antagonists have been used but death has resulted, the poor outcome may have resulted from unopposed o:-adrenergic activity on peripheral vasculature with an increase in peripheral vascular resistance producing acute myocardial failure. 10.11 As f)-antagonists are potentially harmful in some patients, we chose an ultra-short-acting f)-antagonist with an half-life of only nine minutes. 12 The short halflife of the drug' provides advantages over other f)-antagonists. If unopposed o:-agonistic activity becomes evident, the drug can be rapidly discontinued. Esmolol may therefore be a useful agent in the management of SOA associated with tetanus.
